2022 Videos Archives

We are Invivoscribe – Company Overview

Invivoscribe Marketing2023-02-17T20:45:18-08:00December 30th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

Lab Secrets: The Potential for NGS-based MRD Testing for Acute Lymphoblastic Leukemia – The Austin Experience

Invivoscribe Marketing2022-11-18T23:16:58-08:00November 15th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

Development and Implementation of an Automated and Highly Accurate Reporting Process for NGS-based Clonality Testing

wmm2023-01-16T21:30:16-08:00November 2nd, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

High-Throughput Sequencing of TCR Gene Rearrangements as a Useful Tool for Identifying and Tracking Minimal/Measurable Residual Disease (MRD) in Lymphoid Malignancies

wmm2023-01-16T21:27:56-08:00November 2nd, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

NGS-based Clinical Assessment of B- and T-cell Clonality and MRD Determination

wmm2022-10-27T04:25:21-07:00October 26th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

A Comprehensive Solution for AML Precision Diagnostics

Invivoscribe Marketing2022-08-02T14:52:04-07:00July 20th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

Next-generation sequencing of immunoglobulin genes in lymphoid malignancies

Invivoscribe Marketing2022-05-25T03:00:57-07:00May 19th, 2022|2022 Videos, Featured Videos, Videos|

Watch video

Corporate Overview

Invivoscribe Marketing2022-05-25T03:00:57-07:00March 10th, 2022|2022 Videos, Featured Videos, Videos|

Watch video

Lab Secrets: Stratification and Prognoses of Leukemia and Multiple Myeloma using Next-Generation Sequencing (NGS)

Invivoscribe Marketing2022-05-25T03:00:57-07:00February 24th, 2022|2022 Videos, Featured Videos, Videos|

Watch video

Review of Guidelines for Interpreting Somatic Hypermutation Status in Chronic Lymphocytic Leukemia in the Era of High-Throughput Sequencing

Invivoscribe Marketing2022-05-25T03:00:57-07:00January 26th, 2022|2022 Videos, Featured Videos, Videos|

Watch video

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

We are Invivoscribe – Company Overview

Lab Secrets: The Potential for NGS-based MRD Testing for Acute Lymphoblastic Leukemia – The Austin Experience

Development and Implementation of an Automated and Highly Accurate Reporting Process for NGS-based Clonality Testing

High-Throughput Sequencing of TCR Gene Rearrangements as a Useful Tool for Identifying and Tracking Minimal/Measurable Residual Disease (MRD) in Lymphoid Malignancies

NGS-based Clinical Assessment of B- and T-cell Clonality and MRD Determination

A Comprehensive Solution for AML Precision Diagnostics

Next-generation sequencing of immunoglobulin genes in lymphoid malignancies

Corporate Overview

Lab Secrets: Stratification and Prognoses of Leukemia and Multiple Myeloma using Next-Generation Sequencing (NGS)

Review of Guidelines for Interpreting Somatic Hypermutation Status in Chronic Lymphocytic Leukemia in the Era of High-Throughput Sequencing

Title

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Title

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing